Companies › Sarepta Therapeutics
4 active drug programs in 7 registered trials: 3 Phase 3, 3 Phase 1, 1 Phase 4; Neurology, Hematology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| delandistrogene moxeparvovec Dystrophin exogenous gene | DMD | Phase 4 | Duchenne Muscular Dystrophy | May 2027 |
| SRP-9003 Gene transfer therapy encoding beta-sarcoglycan (β-SG); scAAVrh74.MHCK7.hSGCB | SGCB | Phase 3 | Limb-girdle Muscular Dystrophy; Limb Girdle Muscular Dystrophy | Aug 2028 |
| Eteplirsen Dystrophin pre-mRNA positive modulator | DMD | Phase 3 | Muscular Dystrophy, Duchenne | – |
| SRP-1005 | – | Phase 1 | Huntington's Disease | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03992430 | Eteplirsen | Phase 3 | Muscular Dystrophy, Duchenne | Hematology | Oct 2026 |
| NCT05881408 | delandistrogene moxeparvovec | Phase 3 | Duchenne Muscular Dystrophy | Neurology | May 2027 |
| NCT07542314 | delandistrogene moxeparvovec | Phase 4 | Duchenne Muscular Dystrophy | Neurology | Aug 2027 |
| NCT07536061 | SRP-1005 | Phase 1 | Huntington's Disease | Neurology | Nov 2027 |
| NCT04626674 | delandistrogene moxeparvovec | Phase 1 | Duchenne Muscular Dystrophy | Neurology | Dec 2027 |
| NCT05876780 | SRP-9003 | Phase 1 | Limb Girdle Muscular Dystrophy | Neurology | Aug 2028 |
| NCT06246513 | SRP-9003 | Phase 3 | Limb-girdle Muscular Dystrophy | Neurology | Nov 2029 |
Cash and short-term investments of $879m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Nippon Shinyaku NS Pharma Dyne Therapeutics Avidity Biosciences Navamedic
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.